Skip to main content

Advertisement

SpringerLink
Log in

Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

A computer-aided diagnosis of bone scintigraphy using a bone scan index (BSI) has not been applied to a diagnosis of anti-resorptive agents-related osteonecrosis of the jaw (ARONJ). The aim of this study was to validate a diagnostic ability of BSI for early-stage ARONJ.

Methods

A total of 44 cancer patients treated with anti-resorptive drugs were evaluated retrospectively. All patients underwent bone scintigraphy and the tracer uptakes were analyzed by BSI. The software BONENAVI (FUJIFILM RI Pharma; EXINIbone, EXINI Diagnostics) could automatically detect abnormal intensities and calculate each regional BSI (rBSI). Among the rBSIs, the largest one in the jaw was manually selected and defined as maximum BSI of the jaw (BSIJmax). Uptake ratio (UR) between the maximum jaw count-to-average forehead count was also calculated. Screening accuracy of ARONJ based on 2 parameters was compared. Receiver operating characteristic analysis and Fisher’s exact test were performed.

Results

The BSIJmax was significantly higher in patients who developed ARONJ than in those who did not, 3 months before the diagnosis of stage 2 ARONJ (p < 0.0001 and p = 0.02 in the maxilla and mandible, respectively). Using the cutoff values of 0.09% in the maxilla and 0.06% in the mandible, BSIJmax for predicting stage 2 ARONJ showed sensitivity and specificity of 88 and 96%, respectively, in the maxilla and 64 and 89%, respectively, in the mandible at 3 months before the diagnosis. The BSIJmax >0.09% and BSIJmax >0.06% in the maxilla and mandible, respectively, were much more frequently observed in patients who subsequently developed stage 2 ARONJ 3 months after the bone scintigraphy than in those who did not (p < 0.0001 and odds ratio = 182 in the maxilla and p < 0.005 and odds ratio = 14 in the mandible). The UR showed comparable diagnostic ability.

Conclusion

The BSIJ provided a new index for evaluating ARONJ. For predicting occurrence of ARONJ, the thresholds of BSIJmax = 0.09 and 0.06% in the maxilla and mandible, respectively, may be used in patients treated with anti-resorptive drugs, and a differential diagnosis including ARONJ is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–7.

    Article  PubMed  Google Scholar 

  2. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142:1243–51.

    Article  CAS  PubMed  Google Scholar 

  3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg. 2009;67:2–12.

    Article  PubMed  Google Scholar 

  4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72:1938–56.

    Article  PubMed  Google Scholar 

  5. Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, et al. Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg. 2014;52:603–8.

    Article  PubMed  Google Scholar 

  6. Schiodt M, Reibel J, Oturai P, Kofod T. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:204–13.

    Article  PubMed  Google Scholar 

  7. Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012;18:621–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Handmaker H, Leonards R. The bone scan in inflammatory osseous disease. Semin Nucl Med. 1976;6:95–105.

    Article  CAS  PubMed  Google Scholar 

  9. Schauwecker DS. The scintigraphic diagnosis of osteomyelitis. AJR Am J Roentgenol. 1992;158:9–18.

    Article  CAS  PubMed  Google Scholar 

  10. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dento maxillo facial radiology. 2006;35:236–43.

    Article  CAS  PubMed  Google Scholar 

  11. Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009;67:75–84.

    Article  PubMed  Google Scholar 

  12. Krishnan A, Arslanoglu A, Yildirm N, Silbergleit R, Aygun N. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. J Comput Assist Tomogr. 2009;33:298–304.

    Article  PubMed  Google Scholar 

  13. O’Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009;67:1363–72.

    Article  PubMed  Google Scholar 

  14. Thomas C, Spanidis M, Engel C, Roos FC, Frees S, Neisius A, et al. Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC). Clin Oral Investig. 2016;20:753–8.

    Article  PubMed  Google Scholar 

  15. Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw. Clin Nucl Med. 2011;36:17–20.

    Article  PubMed  Google Scholar 

  16. Zanglis A, Andreopoulos D, Dima M, Baltas G, Baziotis N. Jaw uptake of technetium-99 methylene diphosphonate in patients on biphosphonates: a word of caution. Hell J Nucl Med. 2007;10:177–80.

    PubMed  Google Scholar 

  17. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med. 2009;50:30–5.

    Article  PubMed  Google Scholar 

  18. Hong CM, Ahn BC, Choi SY, Kim DH, Lee SW, Kwon TG, et al. Implications of three-phase bone scintigraphy for the diagnosis of bisphosphonate-related osteonecrosis of the jaw. Nucl Med Mol Imaging. 2012;46:162–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ohbayashi Y, Nakai F, Iwasaki A, Ogawa T, Yamamoto Y, Nishiyama Y, et al. The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration. Odontology. 2016. doi:10.1007/s10266-016-0279-9.

    PubMed  Google Scholar 

  20. Ohbayashi Y, Miyake M, Sawai F, Minami Y, Iwasaki A, Matsui Y. Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:e31–7.

    Article  PubMed  Google Scholar 

  21. Ristow O, Gerngross C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, et al. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis? J Oral Maxillofac Surg. 2014;72:903–10.

    Article  PubMed  Google Scholar 

  22. Ristow O, Gerngross C, Schwaiger M, Hohlweg-Majert B, Ristow M, Koerdt S, et al. Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw? J Cancer Res Clin Oncol. 2014;140:487–93.

    Article  CAS  PubMed  Google Scholar 

  23. Ristow O, Gerngross C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, et al. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates. Br J Oral Maxillofac Surg. 2014;52:308–13.

    Article  PubMed  Google Scholar 

  24. Lapa C, Linz C, Bluemel C, Mottok A, Mueller-Richter U, Kuebler A, et al. Three-phase bone scintigraphy for imaging osteoradionecrosis of the jaw. Clin Nucl Med. 2014;39:21–5.

    Article  PubMed  Google Scholar 

  25. Sadik M, Suurkula M, Hoglund P, Jarund A, Edenbrandt L. Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study. J Nucl Med. 2009;50:368–75.

    Article  PubMed  Google Scholar 

  26. Nakajima K, Nakajima Y, Horikoshi H, Ueno M, Wakabayashi H, Shiga T, et al. Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project. EJNMMI Res. 2013;3:83.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Scher HI, Morris MJ, Larson S, Heller G. Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol. 2013;10:225–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Erdi YE, Humm JL, Imbriaco M, Yeung H, Larson SM. Quantitative bone metastases analysis based on image segmentation. J Nucl Med. 1997;38:1401–6.

    CAS  PubMed  Google Scholar 

  29. Hutchinson M, O’Ryan F, Chavez V, Lathon PV, Sanchez G, Hatcher DC, et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg. 2010;68:2232–40.

    Article  PubMed  Google Scholar 

  30. Hamada H, Matsuo A, Koizumi T, Satomi T, Chikazu D. A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. J Craniomaxillofac Surg. 2014;42:924–9.

    Article  PubMed  Google Scholar 

  31. Taniguchi T, Ariji Y, Nozawa M, Naitoh M, Kuroiwa Y, Kurita K, et al. Computed tomographic assessment of early changes of the mandible in bisphosphonate-treated patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:362–72.

    Article  PubMed  Google Scholar 

  32. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397–410.

    Article  PubMed  Google Scholar 

  33. Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg. 2010;68:2241–7.

    Article  PubMed  Google Scholar 

  34. Ariji Y, Ariji E. Role of magnetic resonance imaging in diagnosis of bisphosphonate-related osteonecrosis of the jaw. Oral Radiol. 2013;29:111–20.

    Article  Google Scholar 

  35. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol. 2008;26:4634–8.

    Article  PubMed  Google Scholar 

  36. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27:5356–62.

    Article  CAS  PubMed  Google Scholar 

  37. Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, et al. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:195–202.

    Article  PubMed  Google Scholar 

  38. Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2009;20:331–6.

    Article  PubMed  Google Scholar 

  39. Park HS, Lee YJ, Jeong SH, Kwon TG. Density of the alveolar and basal bones of the maxilla and the mandible. Am J Orthod Dentofac Orthop. 2008;133:30–7.

    Article  Google Scholar 

  40. Kim HJ, Yu SK, Lee MH, Lee HJ, Kim HJ, Chung CH. Cortical and cancellous bone thickness on the anterior region of alveolar bone in Korean: a study of dentate human cadavers. J Adv Prosthodont. 2012;4:146–52.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Jiang RF, Zhang L, Cheng B, Huang Z, Li DL, Wang MM, et al. Increased uptake of Tc-99m-methylene diphosphonate in the jaw. Clin Imaging. 2015;39:1068–72.

    Article  PubMed  Google Scholar 

  42. Arias JA, Pardo C, Olmos A, Cuadrado ML, Ruibal A. Dental diseases and radionuclide imaging of the jaws. Nucl Med Commun. 2004;25:305–10.

    Article  PubMed  Google Scholar 

  43. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, et al. “Bis-phossy jaws”—high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg. 2008;36:95–103.

    Article  PubMed  Google Scholar 

  44. Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Sturzenbaum S, et al. Bisphosphonate-related osteonecrosis of the jaws—characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012;40:303–9.

    Article  PubMed  Google Scholar 

  45. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341–7.

    Article  CAS  PubMed  Google Scholar 

  46. Hirshberg A, Buchner A. Metastatic tumours to the oral region. An overview. Euro J Cancer Part B. Oral Oncol. 1995;31b:355–60.

    CAS  Google Scholar 

  47. Pruckmayer M, Glaser C, Marosi C, Leitha T. Mandibular pain as the leading clinical symptom for metastatic disease: nine cases and review of the literature. Ann Oncol. 1998;9:559–64.

    Article  CAS  PubMed  Google Scholar 

  48. Bedogni A, Saia G, Ragazzo M, Bettini G, Capelli P, D’Alessandro E, et al. Bisphosphonate-associated osteonecrosis can hide jaw metastases. Bone. 2007;41:942–5.

    Article  CAS  PubMed  Google Scholar 

  49. Sadik M, Suurkula M, Hoglund P, Jarund A, Edenbrandt L. Quality of planar whole-body bone scan interpretations—a nationwide survey. Eur J Nucl Med Mol Imaging. 2008;35:1464–72.

    Article  PubMed  Google Scholar 

  50. Tow DE, Garcia DA, Jansons D, Sullivan TM, Niederman R. Bone scan in dental diseases. J Nucl Med. 1978;19:845–7.

    CAS  PubMed  Google Scholar 

  51. Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, Choi CM. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2009;65:333–8.

    Article  Google Scholar 

  52. Hakim SG. Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw: is there something missing? Clin Nucl Med. 2012;37:874.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

K. Nakajima has a collaborative research work with FUJIFILM RI Pharma, Co. Ltd., Tokyo, Japan for the development of software. The authors would like to thank Mr. Ronald Belisle for his editorial assistance and preparation of the manuscript.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, 920-8641, Japan

    Satoru Watanabe, Kenichi Nakajima & Seigo Kinuya

  2. Department of Urology, Kanazawa University Hospital, Kanazawa, Japan

    Atsushi Mizokami & Hiroshi Yaegashi

  3. Department of Oral and Maxillofacial Surgery, Kanazawa University Hospital, Kanazawa, Japan

    Natsuyo Noguchi & Shuichi Kawashiri

  4. Department of Breast Oncology, Kanazawa University Hospital, Kanazawa, Japan

    Masafumi Inokuchi

Authors
  1. Satoru Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenichi Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsushi Mizokami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroshi Yaegashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Natsuyo Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuichi Kawashiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masafumi Inokuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seigo Kinuya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoru Watanabe.

Ethics declarations

Conflict of interest

Nothing to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Watanabe, S., Nakajima, K., Mizokami, A. et al. Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis. Ann Nucl Med 31, 201–210 (2017). https://doi.org/10.1007/s12149-016-1145-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-016-1145-0

Keywords

Search

Navigation